- Home
- GMM vs CUE Comparison
GMM vs CUE Comparison
Compare GMM & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- CUE
- Stock Information
- Founded
- GMM 2017
- CUE 2014
- Country
- GMM China
- CUE United States
- Employees
- GMM N/A
- CUE N/A
- Industry
- GMM
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- GMM
- CUE Health Care
- Exchange
- GMM Nasdaq
- CUE Nasdaq
- Market Cap
- GMM 70.8M
- CUE 60.6M
- IPO Year
- GMM 2023
- CUE 2018
- Fundamental
- Price
- GMM $3.23
- CUE $0.78
- Analyst Decision
- GMM
- CUE Strong Buy
- Analyst Count
- GMM 0
- CUE 4
- Target Price
- GMM N/A
- CUE $4.75
- AVG Volume (30 Days)
- GMM 34.9K
- CUE 145.1K
- Earning Date
- GMM 05-16-2025
- CUE 05-08-2025
- Dividend Yield
- GMM N/A
- CUE N/A
- EPS Growth
- GMM 62.17
- CUE N/A
- EPS
- GMM 6.37
- CUE N/A
- Revenue
- GMM $41,360,953.00
- CUE $9,287,000.00
- Revenue This Year
- GMM N/A
- CUE $13.61
- Revenue Next Year
- GMM N/A
- CUE $82.06
- P/E Ratio
- GMM $0.51
- CUE N/A
- Revenue Growth
- GMM 53.82
- CUE 69.16
- 52 Week Low
- GMM $0.21
- CUE $0.45
- 52 Week High
- GMM $4.97
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- GMM 36.14
- CUE 27.21
- Support Level
- GMM $3.00
- CUE $0.95
- Resistance Level
- GMM $4.21
- CUE $1.05
- Average True Range (ATR)
- GMM 0.43
- CUE 0.09
- MACD
- GMM -0.07
- CUE -0.00
- Stochastic Oscillator
- GMM 17.71
- CUE 5.42
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.